Navigation Links
EntreMed Reports Receipt of Third Quarter Royalty Payment
Date:12/11/2009

ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the receipt of $1.7 million in royalty revenue from sales of Thalomid® during the third quarter compared to estimated royalty revenue of $3.3 million. In addition, the Company anticipates a decrease in fourth quarter and projected revenue for fiscal 2009. The difference in estimated and actual revenues for the third quarter will be reflected in the fourth quarter financial results.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

EntreMed also plans to explore the sale of its rights to future royalties from sales of Thalomid® and has instituted additional expense reductions in non-clinical areas. EntreMed will continue ongoing activities in preparation for initiating a Phase II trial in ovarian cancer patients in the second quarter of 2010.

Thalomid® is a registered trademark of Celgene Corporation.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem® in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).


    CONTACT:
    Ginny Dunn
    Associate Director, Corporate Communications & Investor Relations
    EntreMed, Inc.
    240.864.2643

SOURCE EntreMed, Inc.


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to ... recently reported the Company,s operating results for 2015 ... Lonza America , Inc. (the "Lonza ... in the process of consummating an agreement to ...
(Date:2/9/2016)... ... 09, 2016 , ... The American Academy of Thermology (AAT) has ... 2016 AAT Member Certification Qualification Course for Technicians via a two part webinar on ... include a detailed review of hardware, software, and camera setup/operations, aligns with the in-person ...
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
Breaking Biology Technology:
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
Breaking Biology News(10 mins):